Gilles A. Salles

Hematology | Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 561 publications

Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.

Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.

Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology
Published: June 18, 2026

Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.

Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.

Journal: Expert opinion on drug discovery
Published: June 08, 2026

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2026

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: March 13, 2026

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Journal: Transplantation and cellular therapy
Published: March 04, 2026

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Journal: Transplantation and cellular therapy
Published: March 04, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances
Published: February 23, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances
Published: February 23, 2026

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: February 02, 2026

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: February 02, 2026
Showing 1-12 of 561

Last Updated: 09/26/2026